Hopes and failures in front-line advanced HER2-positive gastric cancer therapy

Area of Science:

• Gastroenterology
• Oncology
• Pharmacology

Background:

• Human epidermal growth-factor receptor 2 (HER2) is a key therapeutic target in gastric cancer.
• Trastuzumab-based chemotherapy is the established first-line standard for advanced HER2-positive gastric cancer.
• Ongoing research aims to optimize current treatment strategies and explore novel therapeutic options.

Purpose of the Study:

• To review significant clinical trials on front-line treatment strategies for HER2-positive gastric cancer.
• To focus on the evolution and future directions of first-line therapy.
• To highlight emerging immunotherapy approaches.

Main Methods:

• Review of clinical trials and published literature.
• Analysis of treatment strategies including chemotherapy, targeted therapy, and immunotherapy.
• Focus on first-line treatment regimens for advanced HER2-positive gastric cancer.

Main Results:

• Trastuzumab plus chemotherapy (cisplatin and fluoropyrimidine) is the current first-line standard.
• Studies have investigated optimizing trastuzumab dosage, chemotherapy regimens, and maintenance therapy.
• Emerging data from Phase II trials suggest promising results for combining immune checkpoint inhibitors in first-line treatment.

Conclusions:

• Despite established standards, safe and effective first-line regimens are still being sought.
• Immunotherapy is driving the development towards potential chemotherapy-free strategies for advanced HER2-positive gastric cancer.
• Continued research into novel combinations and treatment modalities is crucial.